FIELD: chemistry.
SUBSTANCE: invention relates to a crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide, where the crystalline form has a powder X-ray diffraction profile, containing three or more peak values 2θ±0.2, selected from the group consisting of: 6.2 °, 9.0 °, 12.3 °, 12.6 °, 15.6 °, 22.1 °, 25.6 °, 26.3 °, 27.0 ° and 27.3 °. Invention also relates to a pharmaceutical composition capable of inhibiting bromodomains, based on said compound and a method for preparation thereof.
EFFECT: obtaining a novel form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide and pharmaceutical composition based on thereon, which can be used in medicine for the treatment of, for example, malignant neoplasms, kidney disease, autoimmune diseases.
26 cl, 6 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BROMDOMAIN INHIBITORS | 2012 |
|
RU2647592C2 |
| BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
| COMPOUND USED AS INHIBITOR OF BROMO-DOMAIN-CONTAINING PROTEINS, AND COMPOSITION | 2018 |
|
RU2818456C1 |
| BROMODOMAIN INHIBITORS | 2017 |
|
RU2741808C2 |
| PYRIDINONE AND PYRIDAZINONE DERIVATIVES | 2012 |
|
RU2632915C2 |
| QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
| SUBSTITUTED PYRROLO [2,3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3,4-D] PYRIDAZIN-4-ONES AS PROTEINKINASE INHIBITORS | 2017 |
|
RU2749038C2 |
| PHARMACEUTICAL COMBINATION CONTAINING ALK INHIBITOR AND SHP2 INHIBITOR | 2018 |
|
RU2769132C2 |
| PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS TAM AND MET KINASE INHIBITORS | 2019 |
|
RU2773611C1 |
| BICYCLIC HETEROCYCLIC COMPOUNDS AND USE THEREOF IN THERAPY | 2014 |
|
RU2696310C1 |
